Experimental therapies with novel compounds in prostate cancer

Poster Session 04

  • Location:
    Room 14c (ICM, Level 1)
  • Chairs:
     F. Claessens, Leuven (BE)
     T.B. Lam, Aberdeen (GB)
     F.R. Santer, Innsbruck (AT)
  • Aims and objectives of this session

    Clinical relevance of experimental therapy studies will be discussed and clinical relevance assessed. Targeting tumour metabolism is a novel innovative strategy for prostate cancer. The potential of novel compounds will be presented in the session.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 38
Preventing occurrence of metastatic disease in rats with locally advanced prostate cancer by immunomodulation and vascular targeted therapy

By: Lindner U.1, Preise D.2, Kudinova N.2, Agaronov A.1, Salomon Y.3, Coleman J.4, Leibovichi D.1

Institutes: 1Kaplan Medical Center, Dept. of Urology, Rehovot, Israel, 2The Weizmann Institute of Science, Dept. of Plant and Environmental Sciences, Rehovot, Israel, 3The Weizmann Institute of Science, Dept. of Biological Regulation, Rehovot, Israel, 4Memorial Sloan-Kettering Cancer Center, Dept. of Surgery, New York, United States of America

* 39
Targeting cell metabolism to improve prostate cancer therapeutics

By: Bedaj M., Rao K., Robson C., McCracken S.

Institutes: Newcastle University, Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom

* 40
Efficacy of prostate cancer compound with novel mechanism of action targeting the DNA binding domain of the androgen receptor

By: Borgmann H., Dalal K., Beraldi E., Cherkasov A., Rennie P., Gleave M.

Institutes: Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

The role of the HER2 and HER3 in prostate cancer and their potential as therapeutic targets

By: Rao K., Alsamraae M., Gaughan L., Robson C., McCracken S.

Institutes: Newcastle University, Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom

Targeting clusterin-associated proteins improve cellular sensitivity to taxane in prostate cancer

By: Takeuchi A., Shiota M., Katsunori T., Inokuchi J., Kashiwagi E., Dejima T., Yokomizo A., Eto M.

Institutes: Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan

Equol, a metabolite converted from daidzein by enterobacteria, has chemopreventive and inhibitory effects against prostate cancer

By: Tatsumi Y.1, Miyake M.2, Hori S.2, Morizawa Y.2, Nakai Y.2, Anai S.2, Torimoto K.2, Fujii T.1, Konishi N.1, Fujimoto K.2

Institutes: 1Nara Medical University, Dept. of Pathology, Kashihara, Japan, 2Nara Medical University, Dept. of Urology, Kashihara, Japan

Allyl isothiocyanate induces reactive oxygen species-mediated autophagy through beclin-1 in human prostate cancer cells

By: Chen H-E.1, Lin J-F.2, Lin Y-C.1, Tsai T-F.1, Chou K-Y.1, Hwang T.I.S.1

Institutes: 1Shin Kong Wu Ho-Su Mem. Hospital, Dept. of Urology, Taipei, Taiwan, 2Shin Kong Wu Ho-Su Mem. Hospital, Central Laboratory, Taipei, Taiwan

Simvastatin inhibits the proliferation, migration and invasion of androgen independent human prostate cancer cells via up-regulation of Annexin A10

By: Miyazawa Y., Sekine Y., Kato H., Furuya Y., Koike H., Matsui H., Shibata Y., Ito K., Suzuki K.

Institutes: Gunma University Graduate School of Medicine, Dept. of Urology, Maebashi, Japan

Ability of plant extracts to reactivate epigenetically silenced genes in prostate cancer cells

By: Schagdarsurengin U., Teuchert L., Nesheim N., Wagenlehner F., Dansranjavin T.

Institutes: Justus Liebig University of Giessen, Dept. of Urology, Pediatric Urology and Andrology, Giessen, Germany

Development of the first model of radical prostatectomy in mouse: A feasibility study with biochemical validation

By: Di Trapani E., Nini A., Russo A., Buono R., Dell’Oglio P., Locatelli I., Castiglione F., La Croce G., Benigni F., Montorsi F., Salonia A., Briganti A., Cavarretta I.T.

Institutes: Urological Research Institute, Irccs San Raffaele Scientific Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy

Summary and context
 F. Claessens, Leuven (BE)